Loading cart...
Hepcdac (Daclatasvir)
Medically reviewed by Sanjay Gangani, B.Pharm, CMO & Pharmacist
| Active Ingredient | Daclatasvir |
|---|---|
| Indication | Chronic hepatitis C virus (HCV) infection |
| Manufacturer | Cipla Limited |
| Packaging | 28 tablets in 1 bottle |
| Dosage Form:- | Tablet |
| Country of Origin | India |
Hepcdac (Daclatasvir) | ||||
|---|---|---|---|---|
| Pack Size | Price | Quantity | Add To Cart | |
| 28 Tablet/s | $113 | |||
| 56 Tablet/s | $175 | |||
| 84 Tablet/s | $256 | |||
What This Medicine Is
How It Works, and Why It Needs a Partner
The reasoning is straightforward:
Dosage Guide
The dose moves in both directions, which is unusual.
| Situation | Dose | Direction | Key Note |
| Standard | 60 mg once daily | Baseline | With or without food |
| With strong CYP3A4 inhibitors | 30 mg once daily | Reduced | Half the standard dose |
| With moderate CYP3A4 inducers | 90 mg once daily | Increased | Half as much again |
| With strong CYP3A inducers | Not to be used | Contraindicated | See the list below |
| Course length | Usually twelve weeks | Not applicable | Longer with cirrhosis |
| Partner medicine | Sofosbuvir 400 mg daily | Always | Never daclatasvir alone |
| Where ribavirin is added | Decompensated cirrhosis | The prescriber | Also post-transplant |
| Children | Studies not performed | Not established | Per one clinic reference |
| Older patients | No specific problems found | Standard dose | Per the same reference |
| Steady state | Reached after about four days | Not applicable | Once-daily dosing |
Why a dose increase is unusual:
The Amiodarone Warning in Detail
| Point | What the Documents State |
| What happens | Severe bradycardia and heart block |
| With what | Daclatasvir, sofosbuvir and amiodarone together |
| Also relevant | Other medicines that lower heart rate |
| Severity | Cases are potentially life threatening |
| When amiodarone may be used | Only where alternatives fail or are contraindicated |
| If it must be used | Patients are closely monitored at initiation |
| Also applies to | Anyone who stopped amiodarone in recent months |
| Why | The medicine persists long after it is stopped |
| Greater risk if | A beta-blocker is also being taken |
| The clinic position | Coadministration is not advised |
What bradycardia feels like:
What this means in practice:
Precautions
Medicines That Must Not Be Combined
Other Points From the Sources
Before-Use Checklist
Side Effects
Effects named on one Indian pharmacy page:
| Effect | Category | What It Feels Like | What to Do |
| Headache | Named | Head pain | Report if persistent |
| Fatigue | Named | Tiredness | Common during treatment |
| Weakness | Named | Reduced strength | Report if marked |
| Nausea | Named | Queasy stomach | Report if persistent |
| Diarrhoea | Named | Loose stools | Report if persistent |
| Dizziness | Named | Light-headedness | May signal a slow pulse |
| Lightheadedness | Named | Feeling faint | May signal a slow pulse |
| Confusion | Named | Difficulty thinking clearly | Report promptly |
| Chest pain | Named | Pain or discomfort | Seek urgent assessment |
| Shortness of breath | Named | Breathlessness | Seek urgent assessment |
| Severe bradycardia | Serious | Very slow heartbeat | Emergency – seek care |
| Hepatitis B reactivation | Serious | Jaundice, worsening tests | Monitored by the specialist |
A point about four of those entries:
Warning Signs – Seek Medical Help
Seek urgent care if you have:
Why completing the course matters:
Pricing, and a Calculation Problem
| Maker | Pack Price | Stated Per Tablet |
| Aprazer Healthcare | About 3,500 rupees | About 102.50 rupees |
| Zydus Healthcare | About 5,000 rupees | About 146.43 rupees |
| Mylan Pharmaceuticals | About 5,000 rupees | About 146.43 rupees |
| Natco Pharma | About 6,000 rupees | About 175.71 rupees |
| Hetero, Strides and Dr Reddy’s | About 6,000 rupees | About 175.71 rupees |
| Cipla | About 7,000 rupees | About 205.00 rupees |
| Torrent Pharmaceuticals | About 6,000 rupees | About 214.29 rupees |
The figures do not divide consistently:
An Honest Assessment for the Retailer
What can fairly be said:
What a buyer must be told plainly:

Reviews
There are no reviews yet.